ARTMS Products Inc. and Telix Pharmaceuticals Limited announced that they have entered into a development collaboration agreement to employ ARTMS’ high activity production of Gallium-68 (68Ga) for the manufacture of Telix’s prostate cancer imaging product TLX591-CDx (68Ga-PSMA-11 injection) for the imaging of prostate cancer with Positron Emission Tomography (PET).
ARTMS’ flagship product, the QUANTM Irradiation System™ (QIS™) provides cost-effective, decentralized, local production of important medical isotopes, including 68Ga . ARTMS has recently presented data demonstrating industry leading multi-curie production of 68Ga following less than two hours of cyclotron irradiation time. Under the terms of the agreement, ARTMS’ cyclotron technology will be used to produce high-activity 68Ga which will then be validated for use with Telix’s production process for TLX591-CDx.
As part of the collaboration, ARTMS will also provide technical personnel to assist with Zinc-68 (68Zn) solid target irradiations and will utilize its intellectual property for high activity 68Ga processing. Telix will provide technical radiochemistry expertise to oversee radiolabeling and release testing of the final imaging product. Both parties intend to use the results of the collaboration in future marketing authorization applications and promotional activity.
ARTMS’ approach to 68Ga production is changing the way cancer is managed and is expected to be widely commercialized as a leading imaging isotope.
The clinical demand for 68Ga is growing exponentially and cyclotron-based approaches are likely to be an important complement to the use of 68Ge/68Ga generators.